Inozyme Pharma/INZY

$6.84

11.94%
-
1D1W1MYTD1YMAX

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies. Its INZ-701 is in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is designed to increase circulating levels of plasma pyrophosphate (PPi), and adenosine.

Ticker

INZY

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Douglas Treco

Employees

56

Headquarters

Boston, United States

Inozyme Pharma Metrics

BasicAdvanced
$352.65M
Market cap
-
P/E ratio
-$1.46
EPS
1.29
Beta
-
Dividend rate

What the Analysts think about Inozyme Pharma

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 5 analysts.
201.17% upside
High $40.00
Low $15.00
$6.84
Current price
$20.60
Average price target

Inozyme Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-16.6M
7.1%
Profit margin
0%
-

Inozyme Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.31%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.42
-$0.40
-$0.35
-$0.29
-
Expected
-$0.45
-$0.45
-$0.43
-$0.32
-$0.32
Surprise
-7.01%
-10.31%
-19.17%
-8.31%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Inozyme Pharma stock

Buy or sell Inozyme Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing